Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

UnitedHealth Extends Partnership With Somatus Offering Kidney Care To 5 New States – $UNH $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, UnitedHealth Group Incorporated (UNH) and Somatus, Inc., a value-based kidney care company, have expanded their partnership to provide advanced kidney care services to five new states. The partnership will benefit thousands of new members throughout Connecticut, Illinois, Massachusetts, Rhode Island, and New Jersey suffering from chronic kidney disease or end-stage kidney disease.

Somatus’ partnership with UnitedHealthcare expands the company’s geographic footprint to 36 states, including D.C., and increases the number of program members to more than 160,000 under management in 2023. 

“We are excited to expand our partnership with UnitedHealthcare and to offer our outcomes-based medical management program to more UnitedHealthcare members living with kidney disease. This expanded agreement is an incredible opportunity to carry out our mission of creating an individualized approach to treating kidney disease that integrates care and allows people to live the healthier lives they deserve,” stated Dr. Ikenna Okezie, Chief Executive Officer and Co-Founder of Somatus.

Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. To learn more about (UNH) please visit the Vista Partners Company Dedicated UNH Coverage Page

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Taiwan is a destination for assisted reproductive technology (ART) throughout Asia and also has the lowest birthrate in the world. Taiwan’s birth rate has dropped as a result of similar trends elsewhere in Asia, such as later marriage and increasing cost of living. Further, the average age of patients requiring therapy is rising. Fortunately, according to the statistics published by “ICMART”, the overall implantation rate of therapy in Taiwan ranked second worldwide, almost equal to the level in the U.S., and a leading country in Asia. The stable high success rate derives from updated medical research and enriched clinical experience from the physicians, advanced laboratory facilities and technology as well as patient-centered customized treatment plans (depending on their age, ovarian functions and causes of infertility, etc.). Prior to the pandemic, in 2019 there were approximately 55,000 ART cases in Taiwan, an increase of approximately 55% compared to 2016. In July 2021, the government in Taiwan implemented a subsidy plan for ART with the goal of encouraging more local married couples to undergo ART treatments. The subsidies are also available to transnational couples in which one spouse holds a Taiwanese ID card.


INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as “IVC”, provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. INVO believes the IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization (“IVF”) and is a significantly more effective treatment than intrauterine insemination (“IUI”).

INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”) procedure it enables, announced in January, 2023 that it has entered an exclusive distribution agreement with Ming Mei Technology Co. Ltd (“Ming Mei”) for Taiwan. The agreement will have an initial 1-year term with renewals. Ming Mei is a leading distributor of fertility-based devices and components in Taiwan helping to bring the latest and most advanced medical equipment into the region. Ming Mei estimates it has approximately 90% coverage of reagents and consumables in the reproductive medicine market in Taiwan. With strong customer relationships in the region, and their familiarity with the field of reproductive medicine, Ming Mei is ideally suited to expand distribution of INVOcell in Taiwan. 

Learn more by clicking here. 

(Read Original Story: Somatus and UnitedHealthcare Expand Value-Based Kidney Care Agreement to Five New States in PR Newswire)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us